NIH Center for Cancer Research: Clinical Trial Researching Immunotherapy for Solid Tumors
January 15, 2025
January 15, 2025
BETHESDA, Maryland, Jan. 15 (TNSres) -- The National Institutes of Health Center for Cancer Research issued the following news:
ANK-101 is an anchored IL-12 immunotherapy designed for limited intratumoral delivery to increase immune cell infiltration into tumors. It may also be effective when paired with cemiplimab for certain patients.
A clinical trial led by Danielle M. Pastor, D.O., Ph.D., Assistant Research Physician in the Center for Immuno-Oncology, is researching . . .
ANK-101 is an anchored IL-12 immunotherapy designed for limited intratumoral delivery to increase immune cell infiltration into tumors. It may also be effective when paired with cemiplimab for certain patients.
A clinical trial led by Danielle M. Pastor, D.O., Ph.D., Assistant Research Physician in the Center for Immuno-Oncology, is researching . . .